Saladax Biomedical Expands Executive Team with New VP of Clinical Development and Regulatory Affairs
Gary Feiss joins Saladax Biomedical to lead clinical development for the MYCARE™ portfolio of personalized medicine assays, as well as supporting companion diagnostic development programs undertaken in collaboration with pharmaceutical partners.
Bethlehem, PA, April 19, 2010 --(PR.com)-- Gary Lee Feiss Joins Saladax to Lead Clinical Development for MYCARE™ Portfolio of Personalized Medicine Assays
Saladax Biomedical, Inc. (http://www.saladax.com) added a new member to its management team - Vice President of Clinical Development and Regulatory Affairs, Gary Lee Feiss. Saladax is proud to welcome Mr. Feiss, a dynamic professional who will help guide the Company's continued growth.
"Gary Feiss is an enormous asset to the Saladax team," said CEO, Dr. Salvatore J. Salamone. "His background in developing and managing clinical trials brings a new dimension to the Company. Gary’s experience spans the in vitro diagnostic, pharmaceutical and contract research industries, bringing a great understanding of the drivers of success in his new role at Saladax. We are very excited to have him with us."
Mr. Feiss’s primary focus in his new position will be developing supporting clinical validation of the Saladax MYCARE™ line of fifteen personalized medicine diagnostics for optimized drug dosing, as well as supporting companion diagnostic development programs undertaken in collaboration with pharmaceutical partners. He will also oversee global regulatory compliance and product approval activities on behalf of the Company.
Mr. Feiss comes to Saladax with a noteworthy career and over twenty years’ experience in healthcare, most recently serving as Director of Clinical Trials at Orasure Technologies, where he oversaw the clinical development activities for the Hepatitis C Antibody rapid test for the PMA submission and CE marking approval, as well as the clinical trials activities for the OraQuick ADVANCE HIV 1/2 Antibody Test Over-the-Counter program. Prior to that, he served as Associate Vice President & Head of Clinical Development and Regulatory Affairs at sanofi-aventis, Vice President of Regulatory Affairs at Covalent Group, and held positions in Bioglan Pharma and Aventis Pharma (formerly Rhone-Poulenc Rorer). Over this tenure he has had significant contributions to the regulatory approvals of multiple new drugs and medical devices in the US and internationally.
About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic tests for the practical delivery of personalized medicine and companion diagnostics. The Company's MYCARE™ platform of tests increase efficacy and reduce toxicity of existing and emerging therapeutics by helping physicians objectively optimize patient drug dosing. The Company also works with pharmaceutical companies to develop companion diagnostics (CDx) to achieve optimal patient benefit for drugs in the development pipeline. Saladax applies its validated technology platform to generate tests that improve outcomes on a patient by patient basis. Because no two patients are alike.
For more information about Saladax, visit http://www.saladax.com or view their video at http://www.saladax.com/saladaxvideo
Adrienne Choma, Saladax Biomedical, Inc.
achoma@saladax.com; 201 240-4072
###
Saladax Biomedical, Inc. (http://www.saladax.com) added a new member to its management team - Vice President of Clinical Development and Regulatory Affairs, Gary Lee Feiss. Saladax is proud to welcome Mr. Feiss, a dynamic professional who will help guide the Company's continued growth.
"Gary Feiss is an enormous asset to the Saladax team," said CEO, Dr. Salvatore J. Salamone. "His background in developing and managing clinical trials brings a new dimension to the Company. Gary’s experience spans the in vitro diagnostic, pharmaceutical and contract research industries, bringing a great understanding of the drivers of success in his new role at Saladax. We are very excited to have him with us."
Mr. Feiss’s primary focus in his new position will be developing supporting clinical validation of the Saladax MYCARE™ line of fifteen personalized medicine diagnostics for optimized drug dosing, as well as supporting companion diagnostic development programs undertaken in collaboration with pharmaceutical partners. He will also oversee global regulatory compliance and product approval activities on behalf of the Company.
Mr. Feiss comes to Saladax with a noteworthy career and over twenty years’ experience in healthcare, most recently serving as Director of Clinical Trials at Orasure Technologies, where he oversaw the clinical development activities for the Hepatitis C Antibody rapid test for the PMA submission and CE marking approval, as well as the clinical trials activities for the OraQuick ADVANCE HIV 1/2 Antibody Test Over-the-Counter program. Prior to that, he served as Associate Vice President & Head of Clinical Development and Regulatory Affairs at sanofi-aventis, Vice President of Regulatory Affairs at Covalent Group, and held positions in Bioglan Pharma and Aventis Pharma (formerly Rhone-Poulenc Rorer). Over this tenure he has had significant contributions to the regulatory approvals of multiple new drugs and medical devices in the US and internationally.
About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic tests for the practical delivery of personalized medicine and companion diagnostics. The Company's MYCARE™ platform of tests increase efficacy and reduce toxicity of existing and emerging therapeutics by helping physicians objectively optimize patient drug dosing. The Company also works with pharmaceutical companies to develop companion diagnostics (CDx) to achieve optimal patient benefit for drugs in the development pipeline. Saladax applies its validated technology platform to generate tests that improve outcomes on a patient by patient basis. Because no two patients are alike.
For more information about Saladax, visit http://www.saladax.com or view their video at http://www.saladax.com/saladaxvideo
Adrienne Choma, Saladax Biomedical, Inc.
achoma@saladax.com; 201 240-4072
###
Contact
Saladax Biomedical, Inc.
Adrienne Choma
201-240-4072
www.saladax.com
Adrienne Choma
201-240-4072
www.saladax.com
Contact
Categories